Next Article in Journal
IL-18 and Cutaneous Inflammatory Diseases
Next Article in Special Issue
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway
Previous Article in Journal
Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model
Previous Article in Special Issue
Henrin A: A New Anti-HIV Ent-Kaurane Diterpene from Pteris henryi
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2015, 16(12), 29345-29356; doi:10.3390/ijms161226176

The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice

1
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Haike Road #501, Shanghai 201203, China
2
Shenyang Pharmaceutical University, Wenhua Road #103, Shenyang 110016, China
3
Takarazuka University of Medical and Health Care, Hanayashiki-Midorigaoka, Takarazuka-City 6660162, Japan
4
East China University of Science and Technology Shanghai, Meilong Road 130, Shanghai 200237, China
*
Authors to whom correspondence should be addressed.
Academic Editor: Ge Zhang
Received: 30 September 2015 / Revised: 5 November 2015 / Accepted: 17 November 2015 / Published: 9 December 2015
View Full-Text   |   Download PDF [2532 KB, uploaded 9 December 2015]   |  

Abstract

Our previous study indicated that the combination of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1), the main components of Salvia miltiorrhizae and Panax notoginseng, improves myocardium structure and ventricular function in rats with ischemia/reperfusion injury. The present study aimed to determine the safety of the combined SalB and Rg1 (SalB-Rg1) in mice. The safety of SalB-Rg1 was evaluated through acute toxicity and repeated-dose toxicity. In the acute toxicity study, the up and down procedure was carried out firstly, and then, the Bliss method was applied. In the toxicity study for seven-day repeated treatment of SalB-Rg1, forty Kunming mice were randomly divided into four groups. The intravenous median lethal dose (LD50) of the SalB-Rg1 combination was 1747 mg/kg using the Bliss method. For both the acute toxicity study and the seven-day repeated toxicity study, SalB-Rg1 did not induce significant abnormality on brain, heart, kidney, liver and lung structure at any dose based on H&E stain. There were no significant changes related to the SalB-Rg1 toxicity detected on biochemical parameters for two kinds of toxicity studies. The LD50 in mice was 1747 mg/kg, which was more than one hundred times higher than the effective dose. Both studies of acute toxicity and seven-day repeated dose toxicity indicated the safety of the SalB-Rg1 combination. View Full-Text
Keywords: safety; salvianolic acid B; ginsenoside Rg1; acute toxicity; repeated toxicity safety; salvianolic acid B; ginsenoside Rg1; acute toxicity; repeated toxicity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zhao, Q.; Yang, M.; Deng, Y.; Yu, H.; Wang, L.; Teng, F.; Cho, K.; Ma, H.; Wu, P.; Li, X.; Wu, W.; Liu, X.; Xu, F.; Jiang, B.; Guo, D.-A. The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice. Int. J. Mol. Sci. 2015, 16, 29345-29356.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top